Kalinowski L, Szczepanska-Konkel M, Pawelczyk T, Bizon D, Angielski S
Department of Clinical Biochemistry, Medical University of Gdansk, Poland.
Ren Physiol Biochem. 1995 Sep-Oct;18(5):254-66. doi: 10.1159/000173923.
It was shown that atrial natriuretic factor (ANF)-induced increase in glomerular filtration rate (GFR) is blunted in low sodium diet. We investigated whether saralasin, as an angiotensin II receptor antagonist, or verapamil, as a calcium entry blocker, or theophylline and zaprinast, as inhibitors of cGMP-phosphodiesterase activity, could restore the effect of ANF on GFR increase in low sodium diet rats. ANF alone (5 micrograms/kg bolus then 0.5 micrograms/min/kg BW maintenance) increased diuresis and natriuresis to the same extend in low and normal sodium diet rats but had no GFR-increasing effect in low sodium diet rats. Infusion of ANF in the presence of verapamil, saralasin, theophylline or zaprinast induced a significant increase in GFR and filtration fraction (FF). Administration of verapamil or saralasin alone did not alter GFR and FF whereas theophylline or zaprinast alone resulted in moderate but significant increases in both parameters. The increase of nephrogenous cGMP excretion in response to ANF infusion in low sodium diet rats was markedly lower as compared to normal sodium diet rats (243.4 +/- 43.3 vs. 444.0 +/- 35.6 pmol/min, respectively, p < 0.01). Administration of a selective inhibitor of cGMP-phosphodiesterase activity (zaprinast) abolished the differences in ANF-stimulated nephrogenous cGMP excretion in low and normal sodium diet rats. Basal and peak ANF (0.5 microM)-stimulated cGMP formation by isolated glomeruli was significantly lower in low than normal sodium diet rats (1.4 +/- 0.1 vs. 2.9 +/- 0.2 and 7.1 +/- 0.5 vs. 12.5 +/- 1.1 pmol/mg protein, for basal and ANF-stimulated cGMP formation, respectively; both p < 0.05). Zaprinast both alone and in combination with ANF, potentiated cGMP formation by glomeruli isolated from both groups of rats. In the presence of zaprinast, there were no differences in both basal and peak ANF-stimulated cGMP formation by glomeruli isolated from low and normal sodium diet rats. cGMP-phosphodiesterase activity was the same in the medulla of both groups of rats but markedly higher in the renal cortex of low sodium diet rats as compared to normal sodium diet rats (82.6 +/- 6.0 vs. 59.8 +/- 4.3, respectively; p < 0.05). These data suggest that the lack of GFR-increasing response to ANF in low sodium diet rats is primarily due to the increase of cGMP hydrolysis in glomeruli.
研究表明,在低钠饮食条件下,心房利钠因子(ANF)诱导的肾小球滤过率(GFR)增加受到抑制。我们研究了作为血管紧张素II受体拮抗剂的沙拉新、作为钙通道阻滞剂的维拉帕米、以及作为环磷酸鸟苷(cGMP)磷酸二酯酶活性抑制剂的茶碱和扎普司特,是否能恢复ANF对低钠饮食大鼠GFR增加的作用。单独给予ANF(5微克/千克推注,然后以0.5微克/分钟/千克体重维持)在低钠饮食大鼠和正常钠饮食大鼠中增加利尿和利钠作用的程度相同,但对低钠饮食大鼠没有增加GFR的作用。在维拉帕米、沙拉新、茶碱或扎普司特存在的情况下输注ANF可使GFR和滤过分数(FF)显著增加。单独给予维拉帕米或沙拉新不会改变GFR和FF,而单独给予茶碱或扎普司特会使这两个参数适度但显著增加。与正常钠饮食大鼠相比,低钠饮食大鼠在输注ANF后肾源性cGMP排泄的增加明显较低(分别为243.4±43.3与444.0±35.6皮摩尔/分钟,p<0.01)。给予cGMP磷酸二酯酶活性的选择性抑制剂(扎普司特)消除了低钠饮食大鼠和正常钠饮食大鼠在ANF刺激的肾源性cGMP排泄上的差异。低钠饮食大鼠分离的肾小球基础和峰值ANF(0.5微摩尔)刺激的cGMP形成明显低于正常钠饮食大鼠(基础和ANF刺激的cGMP形成分别为1.4±0.1与2.9±0.2以及7.1±0.5与12.5±1.1皮摩尔/毫克蛋白质;两者p<0.05)。扎普司特单独以及与ANF联合使用均增强了两组大鼠分离的肾小球的cGMP形成。在扎普司特存在的情况下,低钠饮食大鼠和正常钠饮食大鼠分离的肾小球在基础和峰值ANF刺激的cGMP形成上没有差异。两组大鼠髓质中的cGMP磷酸二酯酶活性相同,但与正常钠饮食大鼠相比,低钠饮食大鼠肾皮质中的该酶活性明显更高(分别为82.6±6.0与59.8±4.3,p<0.05)。这些数据表明,低钠饮食大鼠对ANF缺乏增加GFR的反应主要是由于肾小球中cGMP水解增加所致。